# Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

> **NCT00409409** · PHASE3 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 278 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** 300 IR grass pollen allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT00409409
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2016-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409409, "Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00409409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*